Literature DB >> 6743782

Apparent dose-dependent oral absorption of cyclosporin A in rats.

C T Ueda, M Lemaire, G Gsell, P Misslin, K Nussbaumer.   

Abstract

The oral absorption of cyclosporin A (CyA) was studied in rats after 6, 12, 18, and 23 mg kg-1 doses were given in an olive oil solution to determine if CyA absorption from the gastrointestinal tract was dose-dependent. Using serial blood samples obtained at various times after the respective doses, analysis of the resultant blood CyA concentration-time curves suggested that the rate of CyA absorption for all four doses was an apparent zero-order process. Moreover, the rate of CyA absorption appeared to be dose-dependent, increasing as the dose of CyA increased. Similarly, the extent of CyA absorption (F) also exhibited dose-dependent characteristics in this study. F increased from 0.13 after the 6 mg kg-1 dose to 0.22 with the 18 and 23 mg kg-1 doses (p less than 0.05). In the present investigation, the observed values for the duration of drug absorption (T), terminal first-order rate constant (beta) and corresponding elimination half-life (T 1/2 beta) of approximately 4-5 h, 0.030 h-1 and 21-28 h, respectively, were similar for all CyA doses. Moreover, no difference in beta was observed after oral or intravenous drug administration. Absorption lag times of 1-2 h were found. The results suggested that the dose-dependent absorption of CyA observed in the present study was possibly related to the effects of olive oil on gastric emptying and that CyA might be unstable in the gastric fluids and/or metabolized by the gastric mucosa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743782     DOI: 10.1002/bdd.2510050207

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  13 in total

Review 1.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

3.  Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Authors:  J Alsenz; H Steffen; R Alex
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

4.  Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size.

Authors:  B D Tarr; S H Yalkowsky
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

5.  On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers.

Authors:  J P Reymond; J L Steimer; W Niederberger
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

6.  Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients.

Authors:  S K Gupta; B Legg; L R Solomon; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

7.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 8.  Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications.

Authors:  P O Gubbins; K E Bertch
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

9.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

10.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.